Topiramate and Nephrolithiasis: A Response

@article{Raff2015TopiramateAN,
  title={Topiramate and Nephrolithiasis: A Response},
  author={Amanda C. Raff and Yasmin Idu Jion and Brian M. Grosberg and Randolph W. Evans},
  journal={Headache: The Journal of Head and Face Pain},
  year={2015},
  volume={55}
}
1. Jion YI, Raff A, Grosberg BM, Evans RW. The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension. Headache. 2015; 55: 161–166. 2. Kaplon DM, Penniston KL, Nakada SY. Patients with and without prior urolithiasis have hypocitraturia and incident kidney stones while on topiramate. Urology. 2011; 77:295-298. 3. Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use… 
1 Citations

References

SHOWING 1-8 OF 8 REFERENCES

Urolithiasis with topiramate in nonambulatory children and young adults.

Increased propensity for calcium phosphate kidney stones with topiramate use

Because the drug is among the most frequently prescribed agents in the US, more controlled studies are required to determine the prevalence of kidney stone disease among TPM users, and the optimal approach to prevent and treat nephrolithiasis in these individuals.

The Risk and Management of Kidney Stones From the Use of Topiramate and Zonisamide in Migraine and Idiopathic Intracranial Hypertension

A 40-year-old woman has a 15-year history of migraine without aura that has been chronic for 5 years and develops a first-time kidney stone that passed spontaneously while on TPM 100 mg daily.

Nephrolithiasis in topiramate users

The prevalence of symptomatic nephrolithiasis with long-term topiramate use is higher than reported in short-term studies and clinical prevalence is underestimated due to asymptomatic nephalisticiasis.

Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review

The use of topiramate, which is prescribed for the management of epilepsy, for migraine headache prophylaxis and as a weight‐loss agent, has been associated with the development of metabolic

Renal Tubular Acidosis and Stone Formation

The syndrome is characterized by a persistent hyperchloremic, normal plasma anion gap and metabolic acidosis in patients with relatively normal glomerular filtration rate, and most patients are associated with recurrent calcium oxalate or calcium phosphate stone formation and nephrocalcinosis.